NYMOX PHARMACEUTICAL CORPORATION (NYMXF) Revenue 2016–2024
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$0FY2024 · since FY2016: $2.8M → $0
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $0 | — |
| FY2023 | $0 | — |
| FY2022 | $0 | -100.0% |
| FY2021 | $5,000 | -95.7% |
| FY2020 | $116,000 | -61.2% |
| FY2019 | $299,000 | +33.5% |
| FY2018 | $224,000 | -21.1% |
| FY2017 | $284,000 | -89.7% |
| FY2016 | $2.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NYMXF financial trends
NYMXF Net incomeNYMXF Net marginNYMXF Gross profitNYMXF Gross marginNYMXF Operating incomeNYMXF Operating marginNYMXF Operating cash flowNYMXF Free cash flowNYMXF Capital expendituresNYMXF Return on equityNYMXF Stock buybacksNYMXF Dividends paidNYMXF Total assetsNYMXF Total liabilitiesNYMXF Shareholders’ equityNYMXF overview →